Review on antimicrobial combination of sulbactam/durlobactam

Abstract

Sulbactam/durlobactam, is a co-packaged antibacterial drug that was approved for the
treatment of infections caused by Acinetobacter baumannii-calcoaceticus complex. Co-administration of
durlobactam with sulbactam prevents sulbactam degradation by β-lactamases. In May 2023, this β-
lactam/β-lactamase inhibitor combination was approved in the United States of America for use in
patients 18 years of age and older for the management of hospital-acquired bacterial pneumonia and
ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumanniicalcoaceticus complex. This review summarizes the mechanism, clinical studies, pharmacology, and
interaction of sulbactam/durlobactam